T. Čufer

发表

Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer.

J. Foekens, J. Klijn, Yixin Wang, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic and predictive value of the urokinase-type plasminogen activator (uPA) and its inhibitors PAI-1 and PAI-2 in operable breast cancer.

T. Čufer, S. Borstnar, I. Vrhovec, 2003, The International journal of biological markers.

Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients.

N. Brünner, M. Fernö, J. Foekens, 2002, Journal of the National Cancer Institute.

Prognostic value of plasminogen activator inhibitors in breast cancer.

T. Čufer, S. Borstnar, I. Vrhovec, 2002, The International journal of biological markers.

Prognostic significance of plasminogen activator inhibitor-1 in breast cancer, with special emphasis on locoregional recurrence-free survival.

T. Čufer, S. Borstnar, I. Vrhovec, 2002, The International journal of biological markers.

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

S Senan, K. Kerr, S. Novello, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy

Tanja Cufer, Manfred Schmitt, Nadia Harbeck, 2009, Breast Cancer Research and Treatment.

Reducing the risk of late recurrence in hormone-responsive breast cancer.

T. Čufer, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Expression of FGFR1–4 in Malignant Pleural Mesothelioma Tissue and Corresponding Cell Lines and its Relationship to Patient Survival and FGFR Inhibitor Sensitivity

C. Pirker, W. Berger, W. Klepetko, 2019, Cells.

Current landscape of ESMO/ASCO Global Curriculum adoption and medical oncology recognition: a global survey

H. Wildiers, P. Rutkowski, T. Čufer, 2021, ESMO open.

Access to Novel Drugs for Non‐Small Cell Lung Cancer in Central and Southeastern Europe: A Central European Cooperative Oncology Group Analysis

J. Jassem, T. Ciuleanu, T. Čufer, 2019, The oncologist.

Lung Cancer in Slovenia.

V. Zadnik, T. Čufer, I. Kern, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Access to Novel Drugs for Non‐Small Cell Lung Cancer in Central and Southeastern Europe: A Central European Cooperative Oncology Group Analysis

J. Jassem, T. Ciuleanu, T. Čufer, 2019, The oncologist.

Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group.

E. Rutgers, R. Paridaens, J. Bogaerts, 2007, European journal of cancer.

Pharmacoeconomic aspects of adjuvant anastrozole or tamoxifen in breast cancer: a Slovenian perspective

T. Čufer, S. Borstnar, A. Mrhar, 2006, Anti-cancer drugs.

Results of randomized phase II trial combining Iressa® (gefitinib) and arimidex in women with advanced breast cancer (ABC). EORTC protocol 10021.

M. Piccart, J. Bogaerts, L. Mauriac, 2009 .

Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study.

M. Piccart, P. Therasse, H. Bonnefoi, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

M. Piccart, C. Gotay, A. Bottomley, 2005, The Lancet. Oncology.

Interpretation Dose-intensive treatment only has a temporary effect on HRQOL, thus enabling more research on intensive treatment for patients with locally advanced breast cancer. Health-related quality of life in survivors of locally advanced breast cancer: an international randomised controlled

M. Piccart, C. Gotay, A. Bottomley, 2005 .

The American Society of Clinical Oncology's Efforts to Support Global Cancer Medicine.

G. Hortobagyi, T. Čufer, E. Cazap, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Febrile neutropenia in chemotherapy treated small-cell lung cancer patients

T. Čufer, A. Mrhar, I. Grabnar, 2015, Radiology and oncology.

Comparison of gefitinib and docetaxel in patients with pretreated advanced non-small cell lung cancer (NSCLC): Meta-analysis from four clinical trials.

Edward S. Kim, N. Saijo, A. Armour, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical outcome of breast cancer patients with liver metastases alone in the anthracycline-taxane era: a retrospective analysis of two prospective, randomised metastatic breast cancer trials.

M. Piccart, R. Paridaens, P. Therasse, 2003, European journal of cancer.

Moonshot or groundshot: addressing Europe's cancer challenge through a patient-focused, data-enabled lens.

M. Aapro, J. Jassem, M. Lawler, 2019, The Lancet. Oncology.

Insulin-like Growth Factor 1 Receptor Expression in Advanced Non-small-cell Lung Cancer and its Impact on Overall Survival

T. Čufer, I. Kern, G. Vlacic, 2017, Radiology and oncology.

International Guidelines for Management of Metastatic Breast Cancer: Can Metastatic Breast Cancer Be Cured?

E. Winer, F. Cardoso, Alberto Costa, 2010, Journal of the National Cancer Institute.

Adjuvant treatment of breast cancer patients with trastuzumab

T. Čufer, E. Matos, 2007 .

Invasive bladder cancer: our experience with bladder sparing approach.

T. Čufer, S. Borstnar, B. Kragelj, 1998, International journal of radiation oncology, biology, physics.

Results from a phase II, open-label, randomized study (SIGN) comparing gefitinib with docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer

T. Čufer, E. Vrdoljak, 2005 .

Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program

A. Valipour, A. Addeo, T. Čufer, 2022, Therapeutic Advances in Medical Oncology.

Pooled analysis of prognostic impact of uPA and PAI-1 in breast cancer patients

N. Brünner, M. Fernö, J. Foekens, 2003, Thrombosis and Haemostasis.

Anti-tumor activity of capecitabine and vinorelbine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: findings from the EORTC 10001 randomized phase II trial.

P. Ellis, M. Piccart, J. Bogaerts, 2008, Breast.

An EORTC phase I study of capecitabine (Xeloda) in combination with fixed doses of cyclophosphamide and epirubicin (cex) as primary treatment for large operable or locally advanced/inflammatory breast cancer.

M. Piccart, H. Bonnefoi, L. Mauriac, 2003, European journal of cancer.

Prognostic impact of PD-1 and PD-L1 expression in malignant pleural mesothelioma: an international multicenter study

W. Berger, W. Klepetko, T. Čufer, 2021, Translational lung cancer research.

The PARAMOUNT study and the re-challenge chemotherapy issue in advanced non-small cell lung cancer.

T. Čufer, M. O'Brien, 2013, European journal of cancer.

Limitations of cancer care in Central and South-Eastern Europe: results of the international conference organized by the Central European Cooperative Oncology Group (CECOG)

J. Jassem, T. Čufer, N. Wilking, 2020, Journal of Health Inequalities.

Definition of synchronous oligo-metastatic non-small cell lung cancer - a consensus report.

C. Dooms, N. Girard, H. Gietema, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Systemic therapy of advanced non-small cell lung cancer: major-developments of the last 5-years.

Tanja Cufer, T. Čufer, M. O'Brien, 2013, European Journal of Cancer.

The impact of new European Organisation for Research and Treatment of Cancer guidelines on the use of granulocyte colony-stimulating factor on the management of breast cancer patients.

M. Aapro, D. Cameron, T. Čufer, 2008, European journal of cancer.

Randomized, controlled trial investigating short-term health-related quality of life with doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: European Organization for Research and Treatment of Cancer Breast Cancer

M. Piccart, A. Bottomley, T. Čufer, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Decreased cortisol secretion by adrenal glands perfused with the P-glycoprotein inhibitor valspodar and mitotane or doxorubicin

B. Sikic, T. Čufer, R. Golouh, 2000, Anti-cancer drugs.

Effect of the multidrug resistance modulator valspodar on serum cortisol levels in rabbits

B. Sikic, T. Čufer, S. Borstnar, 1998, Cancer Chemotherapy and Pharmacology.

Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of ≥1% by the USA Food and Drug Administration.

S. Novello, J. Vansteenkiste, T. Čufer, 2019 .

Cyclophosphamide (C) - Epirubicine (E) - Capecitabine (X) combination, CEX: A safe and active regimen in the treatment of locally advanced/inflammatory (LA/I) or large operable (LO) breast cancer (BC). An EORTC-IDBBC study

M. Piccart, H. Bonnefoi, L. Mauriac, 2001 .

Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small cell lung cancer with a PD-L1 expression level of ≥ 1% by the U.S. Food and Drug Administration.

S. Novello, J. Vansteenkiste, T. Čufer, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts) - A randomized phase III trial of the EORTC Breast Group

M. Piccart, M. Nooij, R. Paridaens, 2004 .

Implementing new clinical pharmacy services parallel to the introduction of centralized preparation of anti-cancer drugs

N. Triller, T. Čufer, L. Knez, 2011 .

Real-life Long-term Outcomes of Upfront Surgery in Patients with Resectable Stage I-IIIA Non-small Cell Lung Cancer

T. Čufer, I. Kern, A. Sadikov, 2022, Radiology and oncology.

The ESSO core curriculum committee update on surgical oncology.

R. Audisio, K. Søreide, G. Beets, 2021, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Adjuvant endocrine therapy for perimenopausal women with early breast cancer.

H. Wildiers, J. Dixon, V. Semiglazov, 2009, Breast.

Population pharmacokinetics of cisplatin in small cell lung cancer patients guided with informative priors

T. Čufer, I. Grabnar, T. Vovk, 2022, Cancer Chemotherapy and Pharmacology.

Accelerating the Development and Validation of Liquid Biopsy for Early Cancer Screening and Treatment Tailoring

F. Gatto, T. Čufer, D. Verbanac, 2022, Healthcare.

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2).

L. V. van't Veer, M. Piccart, C. Hudis, 2014, Breast.

Outcome of small cell lung cancer (SCLC) patients with brain metastases in a routine clinical setting

N. Triller, T. Čufer, A. Sadikov, 2012, Radiology and oncology.

Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer. First results of a randomized phase III trial EORTC 10901

E. Rutgers, R. Paridaens, P. Therasse, 2004 .

Brain metastases in lung adenocarcinoma: impact of EGFR mutation status on incidence and survival

T. Čufer, I. Kern, A. Sadikov, 2014, Radiology and oncology.

Doxorubicin-paclitaxel - A safe regimen in terms of cardiac toxicity in metastatic breast carcinoma patients. Results from a European organization for research and treatment of cancer multicenter trial

M. Piccart, M. Nooij, D. Miles, 2003 .

K. Van Steen, M. Piccart, M. Sprangers, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

European Groundshot-addressing Europe's cancer research challenges: a Lancet Oncology Commission.

M. Coleman, G. Lewison, C. la Vecchia, 2022, The Lancet. Oncology.

International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent Chemotherapy

E. Winer, L. Fallowfield, F. Cardoso, 2009, Journal of the National Cancer Institute.

An EORTC phase I study of epirubicin in combination with fixed doses of cyclophosphamide and infusional 5-fu (CEF-infu) as primary treatment of large operable or locally advanced/inflammatory breast cancer

M. Piccart, H. Bonnefoi, L. Mauriac, 2001, Breast Cancer Research and Treatment.

Prognostic and predictive value of cathepsins D and L in operable breast cancer patients.

T. Čufer, S. Borstnar, I. Vrhovec, 2005, Neoplasma.

Combination of 5-Fluorouracil, Imidazole Carboxamide, Bcnu and Prednisolone (FIB-P) as a Salvage Chemotherapy in Heavily Pretreated Breast Cancer Patients

T. Čufer, K. Kolarić, J. Červek, 1992, Tumori.

Proteases and metastasis: clinical relevance nowadays?

R. Paridaens, T. Čufer, J. Decock, 2005, Current opinion in oncology.

MA25.02 Searching for a Definition of Synchronous Oligometastatic (sOMD)-NSCLC: A Consensus from Thoracic Oncology Experts

N. Girard, H. Gietema, G. Scagliotti, 2018, Journal of Thoracic Oncology.

Tumor-Biological Factors Upa and PAI-1 as Stratification Criteria of a Multicenter Adjuvant Chemotherapy Trial in Node-Negative Breast Cancer

C. Meisner, N. Harbeck, M. Untch, 2000, The International journal of biological markers.

High levels of uPA and PAI-1 predict a good response to anthracyclines

Aleksander Sadikov, Tanja Cufer, T. Čufer, 2010, Breast Cancer Research and Treatment.

Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials

Bingshu E. Chen, D. Berry, P. Fasching, 2019, The Lancet.

Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients.

T. Čufer, S. Borstnar, I. Vrhovec, 2002, Clinical breast cancer.

Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial.

L. Harris, A. Wolff, M. Piccart-Gebhart, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High BMI1 mRNA expression in peripheral whole blood is associated with favorable prognosis in advanced non-small cell lung cancer patients

P. Korošec, T. Čufer, I. Kern, 2017, Oncotarget.

Echocardiography and cardiac biomarkers in patients with non-small cell lung cancer treated with platinum-based chemotherapy

T. Čufer, R. Marčun, D. Omersa, 2016, Radiology and oncology.

Cancer Control in Central and Eastern Europe: Current Situation and Recommendations for Improvement.

B. Sikic, J. Jassem, R. Pirker, 2016, The oncologist.

Update on systemic therapy of advanced non-small-cell lung cancer

T. Čufer, L. Knez, 2014, Expert review of anticancer therapy.

Current standards in the treatment of metastatic breast cancer with focus on Lapatinib: a review by a Central European Consensus Panel

R. Vyzula, J. Abrahámová, J. Jassem, 2010, Wiener klinische Wochenschrift.

Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

S. Loibl, V. Nekljudova, Marcus Schmidt, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PD-L1 Expression in Squamous-cell Carcinoma and Adenocarcinoma of the Lung

T. Čufer, I. Kern, U. Janzic, 2017, Radiology and oncology.

BMI1, ALDH1A1, and CD133 Transcripts Connect Epithelial-Mesenchymal Transition to Cancer Stem Cells in Lung Carcinoma

P. Korošec, T. Čufer, I. Kern, 2015, Stem cells international.

A simple dried blood spot method for clinical pharmacological analyses of etoposide in cancer patients using liquid chromatography and fluorescence detection.

T. Čufer, A. Mrhar, I. Grabnar, 2016, Clinica chimica acta; international journal of clinical chemistry.

TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial.

Tanja Cufer, Thierry Petit, Khalil Zaman, 2011, The Lancet. Oncology.

Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients.

J. Foekens, J. Nährig, G. Kristiansen, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Report on EU–USA Workshop: How Systems Biology Can Advance Cancer Research (27 October 2008)

Olaf Wolkenhauer, Blaz Zupan, Ravi Iyengar, 2009, Molecular oncology.

Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group.

M. Piccart, M. Nooij, R. Paridaens, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Imaging of pleural fluid in healthy individuals.

T. Čufer, I. Kocijančič, K. Kocijančič, 2004, Clinical radiology.

International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer.

E. Winer, L. Fallowfield, N. Lin, 2013, Breast.

Mapping cancer research across Central and Eastern Europe, the Russian Federation and Central Asia: Implications for future national cancer control planning.

Grant Lewison, Tanja Cufer, Mark Lawler, 2018, European journal of cancer.

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†

M. Piccart, C. Hudis, L. Norton, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

1st International consensus guidelines for advanced breast cancer (ABC 1).

C. Hudis, L. Norton, K. Gelmon, 2012, Breast.

Oral treatment with etoposide in small cell lung cancer – dilemmas and solutions

T. Čufer, A. Mrhar, L. Knez, 2013, Radiology and oncology.

Extended adjuvant endocrine therapy - A standard to all or some?

F. Cardoso, T. Čufer, B. Sousa, 2017, Breast.

Patterns of genomic change in residual disease after neoadjuvant chemotherapy for estrogen receptor-positive and HER2-negative breast cancer

M. Piccart, G. MacGrogan, K. Zaman, 2021, British Journal of Cancer.

Lung cancer stem cells: a biological and clinical perspective

H. Motaln, T. Čufer, A. Koren, 2013, Cellular Oncology.

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)

Eld, M. Piccart, C. Hudis, 2014, Breast.

Predictive value of ABCB1 polymorphisms G2677T/A, C3435T, and their haplotype in small cell lung cancer patients treated with chemotherapy

T. Čufer, M. Košnik, I. Kern, 2012, Journal of Cancer Research and Clinical Oncology.

Predictive value of multidrug resistance proteins, topoisomerases II and ERCC1 in small cell lung cancer: a systematic review.

T. Čufer, M. Košnik, I. Kern, 2011, Lung cancer.

Prognostic factors in invasive bladder carcinoma treated by combined modality protocol (organ-sparing approach).

T. Čufer, S. Borstnar, B. Kragelj, 2000, International journal of radiation oncology, biology, physics.

The prognostic value of Stathmin-1, S100A2, and SYK proteins in ER-positive primary breast cancer patients treated with adjuvant tamoxifen monotherapy: an immunohistochemical study

N. Brünner, J. Foekens, M. Timmermans, 2008, Breast Cancer Research and Treatment.

Immunotherapy for metastatic non-small cell lung cancer: Real-world data from an academic Central and Eastern European centre.

T. Čufer, M. Ivanović, M. Kovacevic, 2021, The oncologist.

Dynamic Changes of EGFR Activating Mutations as an Early Predictor of Progression in Non–Small Cell Lung Cancer Patients Treated with EGFR Tyrosine Kinase Inhibitors

Aleks, T. Čufer, I. Kern, 2020 .

Epidermal Growth Factor Receptor Mutation-Positive Non–Small-Cell Lung Cancer in the Real-World Setting in Central Europe: The INSIGHT Study

W. Olszewski, H. Popper, R. Dziadziuszko, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Efficacy of tyrosine kinase inhibitors in routine clinical practice: epidermal growth factor mutations and their implications.

T. Čufer, I. Kern, A. Sadikov, 2013, Journal of cancer research and therapeutics.

Immunohistochemistry for EGFR Mutation Detection in Non–Small‐Cell Lung Cancer

T. Čufer, I. Kern, A. Sadikov, 2017, Clinical lung cancer.

Myeloid metaplasia of the breast.

T. Čufer, M. Bračko, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant chemotherapy in 2005: standards and beyond.

M. Piccart, T. Čufer, E. de Azambuja, 2005, Breast.

Lung cancer stem cells: a biological and clinical perspective

H. Motaln, T. Čufer, A. Koren, 2013, Cellular Oncology.

Identifying the Steps Required to Effectively Implement Next-Generation Sequencing in Oncology at a National Level in Europe

K. Kerr, J. V. van Meerbeeck, F. Penault-Llorca, 2022, Journal of personalized medicine.

Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial.

J Bogaerts, J. Bergh, P. Malmström, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer.

M. Piccart, M. Nooij, R. Paridaens, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Biology of Metastasis With Focus on Proteases

T. Čufer, 2005, EJIFCC.

Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer.

S. Loibl, N. Harbeck, V. Nekljudova, 2011, European journal of cancer.

Time to access to novel anticancer drugs and the correlation with ESMO-Magnitude of Clinical Benefit Scale in Slovenia

T. Čufer, U. Janzic, L. Knez, 2019, Expert review of pharmacoeconomics & outcomes research.

First results of a randomized phase III trial comparing exemestane versus tamoxifen as first-line hormone therapy (HT) for postmenopausal women with metastatic breast cancer (MBC) — EORTC 10951 in collaboration with the exemestane working group and NCIC Clinical Trials Group

M. Piccart, R. Paridaens, P. Therasse, 2004 .

Promising results with exemestane in the first-line treatment of metastatic breast cancer: a randomized phase II EORTC trial with a tamoxifen control.

M. Piccart, M. Nooij, R. Paridaens, 2000, Clinical breast cancer.

Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†.

S Michiels, B Asselain, J Bogaerts, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study.

B. Halmos, J. Yang, T. Čufer, 2018, Future oncology.

Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer.

M. Piccart, A. Bottomley, T. Čufer, 2004, European journal of cancer.

Electrochemotherapy with cisplatin of cutaneous tumor lesions in breast cancer

Tanja Cufer, Simona Kranjc, Gregor Sersa, 2004, Anti-cancer drugs.

Electrochemotherapy of chest wall breast cancer recurrence.

Tanja Cufer, Gregor Sersa, Marko Snoj, 2012, Cancer treatment reviews.

NSCLC molecular testing in Central and Eastern European countries

W. Olszewski, R. Dziadziuszko, I. Kovalszky, 2018, BMC Cancer.

Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer

T. Čufer, R. Gaafar, E. Vrdoljak, 2006, Anti-cancer drugs.

Adjuvant therapy of breast cancer: update.

T. Čufer, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic value of cytokeratin-7 mRNA expression in peripheral whole blood of advanced lung adenocarcinoma patients

P. Korošec, T. Čufer, M. Rijavec, 2015, Cellular Oncology.

Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052).

J. V. van Meerbeeck, A. Price, P. Baas, 2013, European journal of cancer.

Phase II study of radiochemotherapy with vinblastine in invasive bladder cancer.

T. Čufer, B. Kragelj, L. Zaletel-Kragelj, 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Capecitabine vs. capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: The TBP phase III study (GBG 26/BIG 3–05)

S. Loibl, T. Čufer, H. Eidtmann, 2008 .

Constitutional alterations of the ATM gene in early onset sporadic breast cancer

P. Chappuis, W. Foulkes, H. Bonnefoi, 2002, Journal of medical genetics.

Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial.

M. Piccart, L. Duchateau, C. Lohrisch, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378).

M. Piccart, J. Bogaerts, D. Cameron, 2016, European journal of cancer.

Cytological grading of breast cancer in Giemsa‐stained fine needle aspiration smears

T. Čufer, M. Us-Krasovec, B. Škrbinc, 2001, Cytopathology : official journal of the British Society for Clinical Cytology.

Impact of ERCC1 expression on treatment outcome in small-cell lung cancer patients treated with platinum-based chemotherapy.

T. Čufer, I. Kern, A. Sadikov, 2012, European journal of cancer.

Prognostic value of cytokeratin-7 mRNA expression in peripheral whole blood of advanced lung adenocarcinoma patients

P. Korošec, T. Čufer, M. Rijavec, 2015, Cellular Oncology.

S‐phase fraction determined on fine needle aspirates is an independent prognostic factor in breast cancer – a multivariate study of 770 patients

M Bracko, M Us-Krasovec, T. Čufer, 2008, Cytopathology.

Achieving Thoracic Oncology data collection in Europe: a precursor study in 35 Countries

P. V. Van Schil, G. Hillerdal, O. Burghuber, 2018, BMC Cancer.

M. Piccart, P. Therasse, H. Bonnefoi, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Current controversies in extended adjuvant endocrine therapy for early breast cancer

R. Paridaens, T. Čufer, N. Snoj, 2008, Current opinion in oncology.

The prognostic value of whole blood SOX2, NANOG and OCT4 mRNA expression in advanced small-cell lung cancer

P. Korošec, T. Čufer, M. Rijavec, 2016, Radiology and oncology.

Gene Expression Levels of the Prolyl Hydroxylase Domain Proteins PHD1 and PHD2 but Not PHD3 Are Decreased in Primary Tumours and Correlate with Poor Prognosis of Patients with Surgically Resected Non-Small-Cell Lung Cancer

P. Korošec, T. Čufer, I. Kern, 2021, Cancers.

Prognostic value of DNA ploidy in breast cancer stage I-II.

J. Lindtner, T. Čufer, M. Us-Krasovec, 1997, Neoplasma.

Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials).

H. Wildiers, J. Bogaerts, J. Yarnold, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Sequential transurethral surgery, multiple drug chemotherapy and radiation therapy for invasive bladder carcinoma: initial report.

T. Čufer, B. Kragelj, B. Zakotnik, 1993, International journal of radiation oncology, biology, physics.

Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: final analysis of the GioTag study.

B. Halmos, J. Yang, T. Čufer, 2020, Future oncology.

Association of Aromatase Inhibitors With Coronary Heart Disease in Women With Early Breast Cancer

V. Zadnik, T. Čufer, A. Ocaña, 2014, Cancer investigation.

Exemestane (Aromasin) is active and well tolerated as first-line hormonal therapy (HT) of metastatic breast cancer (MBC) patients (pts): results of a randomized phase II trial

M. Piccart, M. Nooij, R. Paridaens, 2000 .

Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study.

B. Halmos, J. Yang, T. Čufer, 2019, Future oncology.

The EORTC Breast Cancer Group: major achievements of 50 years of research and future directions

E. Rutgers, L. J. Veer, J. Bogaerts, 2012 .

Doxorubicin/paclitaxel

M. Piccart, M. Nooij, L. Duchateau, 2023, Reactions Weekly.

Guidelines on the standards for the training of specialised health professionals dealing with breast cancer.

C. de Wolf, E. van Limbergen, I. Ellis, 2007, European journal of cancer.

Expenditures on Oncology Drugs and Cancer Mortality-to-Incidence Ratio in Central and Eastern Europe.

B. Sikic, J. Jassem, R. Pirker, 2018, The oncologist.

Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: A double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064).

V. Georgoulias, P. Baas, T. Čufer, 2015, European journal of cancer.

Perspectives for Cancer Care and Research in Central and Eastern Europe

J. Jassem, T. Čufer, C. Thallinger, 2022, Oncology Research and Treatment.

Gynecological Cancers: A Challenge of Individualized Therapy in the Adjuvant and Palliative Setting

Quillien, I. Christensen, N. Harbeck, 2015 .

Real-world outcomes of immunotherapy with or without chemotherapy in first-line treatment of advanced non-small cell lung cancer

T. Čufer, L. Knez, Veronika Pelicon, 2023, Frontiers in Oncology.

Patients and Methods Patient Selection

M. Piccart, P. Therasse, H. Bonnefoi, 2003 .

Barriers and challenges to global clinical cancer research.

T. Čufer, N. Leighl, R. Digumarti, 2014, The oncologist.

An EORTC-IDBBC phase I study of gemcitabine and continuous infusion 5-fluorouracil in patients with metastatic breast cancer resistant to anthracyclines or pre-treated with both anthracyclines and taxanes.

M. Piccart, M. Nooij, L. Beex, 2002, European journal of cancer.

3D Microelectrode Geometry Effects the Multilayer Dense Osteo Intra-organelle Membrane Potential Characterization

J. Gehl, L. Mir, D. Scherman, 2015 .

First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts) - A randomized phase III trial of the EORTC Breast Group.

M. Piccart, M. Nooij, R. Paridaens, 2004, Journal of Clinical Oncology.

Doxorubicin‐paclitaxel

M. Piccart, M. Nooij, L. Duchateau, 2003, Cancer.

International consensus guidelines for advanced breast cancer ( ABC 1 )

L. Norton, A. Goldhirsch, F. Cardoso, 2012 .

Predicting survival with health-related quality of life scores in locally advanced breast cancer: Results from an international randomized controlled trial.

M. Piccart, A. Bottomley, P. Therasse, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Which tools can I use in daily clinical practice to improve tailoring of treatment for breast cancer? The 2007 St Gallen guidelines and/or Adjuvant! Online.

T. Čufer, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Electrochemotherapy with Bleomycin in the Treatment of Hypernephroma Metastasis: Case Report and Literature Review

Gregor Serša, Maja Čemažar, T. Čufer, 2000, Tumori.

Systemic therapy of advanced non-small cell lung cancer: major-developments of the last 5-years.

T. Čufer, M. O'Brien, T. Ovčariček, 2013, European journal of cancer.

Multicenter study validates PITX2 DNA methylation for risk prediction in tamoxifen-treated, node-negative breast cancer using paraffin-embedded tumor tissue

G. Kristiansen, A. Paradiso, N. Harbeck, 2005 .

AT (doxorubicin-Taxol) versus AC (doxorubicin-cyclophosphamide) as first line chemotherapy in metastatic breast cancer (MBC): A phase III study. (originally presented at ASCO 2000. Abstract 282)

L. Duchateau, T. Čufer, C. Twelves, 2000 .

Prognostic significance of DNA ploidy determined by high-resolution flow cytometry in breast carcinoma.

T. Čufer, M. Us-Krasovec, J. Lamovec, 2001, Analytical and quantitative cytology and histology.

Multi-center validation of the 76-gene prognostic signature in lymph node negative (LNN) primary breast cancer

David C. Atkins, J. Foekens, C. Sweep, 2005 .